Ray Dalio's BIIB Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 39,983 shares of Biogen Inc. (BIIB) worth $5.6 M, representing 0.02% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 44 quarters.
Based on 13F filings since 2013, Ray Dalio has maintained a long-term strategic position in BIIB, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2022, adding 230,412 shares. Largest reduction occurred in Q4 2019, reducing 237,455 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Biogen (BIIB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Biogen (BIIB) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +10,513 | Add 0.00% | 10,512 | $215.18 |
| Q3 2013 | -4,338 | Reduce 41.27% | 6,174 | $240.69 |
| Q4 2013 | +12,883 | Add 208.67% | 19,057 | $279.58 |
| Q1 2014 | -19,057 | Sold Out | 0 | $0.00 |
| Q3 2014 | +1,646 | New Buy | 1,646 | $331.11 |
| Q4 2014 | +13,500 | Add 820.17% | 15,146 | $339.43 |
| Q1 2015 | +5,300 | Add 34.99% | 20,446 | $422.23 |
| Q2 2015 | -20,446 | Sold Out | 0 | $0.00 |
| Q3 2015 | +14,766 | New Buy | 14,766 | $291.82 |
| Q4 2015 | +10,340 | Add 70.03% | 25,106 | $306.34 |
| Q1 2016 | -2,000 | Reduce 7.97% | 23,106 | $260.32 |
| Q2 2016 | +28,355 | Add 122.72% | 51,461 | $241.81 |
| Q3 2016 | -50,561 | Reduce 98.25% | 900 | $313.33 |
| Q4 2016 | -900 | Sold Out | 0 | $0.00 |
| Q1 2017 | +45,447 | New Buy | 45,447 | $273.42 |
| Q2 2017 | -466 | Reduce 1.03% | 44,981 | $271.36 |
| Q3 2017 | -783 | Reduce 1.74% | 44,198 | $313.11 |
| Q4 2017 | -44,198 | Sold Out | 0 | $0.00 |
| Q1 2018 | +77,197 | New Buy | 77,197 | $273.82 |
| Q2 2018 | -54,378 | Reduce 70.44% | 22,819 | $290.24 |
| Q3 2018 | -2,387 | Reduce 10.46% | 20,432 | $353.32 |
| Q4 2018 | +25,463 | Add 124.62% | 45,895 | $300.93 |
| Q1 2019 | +194,483 | Add 423.76% | 240,378 | $236.38 |
| Q2 2019 | +8,555 | Add 3.56% | 248,933 | $233.87 |
| Q3 2019 | -11,478 | Reduce 4.61% | 237,455 | $232.82 |
| Q4 2019 | -237,455 | Sold Out | 0 | $0.00 |
| Q1 2021 | +8,397 | New Buy | 8,397 | $279.74 |
| Q2 2021 | +9,459 | Add 112.65% | 17,856 | $346.27 |
| Q3 2021 | -5,234 | Reduce 29.31% | 12,622 | $283.00 |
| Q4 2021 | -218 | Reduce 1.73% | 12,404 | $239.92 |
| Q1 2022 | +25,115 | Add 202.48% | 37,519 | $210.61 |
| Q2 2022 | +230,412 | Add 614.12% | 267,931 | $203.94 |
| Q3 2022 | -154,308 | Reduce 57.59% | 113,623 | $267.00 |
| Q4 2022 | -2,826 | Reduce 2.49% | 110,797 | $276.92 |
| Q1 2023 | +36,928 | Add 33.33% | 147,725 | $278.03 |
| Q2 2023 | -21,306 | Reduce 14.42% | 126,419 | $284.85 |
| Q3 2023 | +24,458 | Add 19.35% | 150,877 | $257.01 |
| Q4 2023 | -7,591 | Reduce 5.03% | 143,286 | $258.77 |
| Q1 2024 | -98,334 | Reduce 68.63% | 44,952 | $215.63 |
| Q2 2024 | -28,536 | Reduce 63.48% | 16,416 | $231.82 |
| Q3 2024 | +55,688 | Add 339.23% | 72,104 | $193.84 |
| Q4 2024 | -2,071 | Reduce 2.87% | 70,033 | $152.92 |
| Q1 2025 | -70,033 | Sold Out | 0 | $0.00 |
| Q3 2025 | +39,983 | New Buy | 39,983 | $140.08 |
Ray Dalio's Biogen Investment FAQs
Ray Dalio first purchased Biogen Inc. (BIIB) in Q2 2013, acquiring 10,512 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Biogen Inc. (BIIB) for 44 quarters since Q2 2013.
Ray Dalio's largest addition to Biogen Inc. (BIIB) was in Q2 2022, adding 267,931 shares worth $54.64 M.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 39,983 shares of Biogen Inc. (BIIB), valued at approximately $5.6 M.
As of the Q3 2025 filing, Biogen Inc. (BIIB) represents approximately 0.02% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Biogen Inc. (BIIB) was 267,931 shares, as reported at the end of Q2 2022.